“In the second quarter we continued to advance our programs across Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy,” said Shoshana Shendelman, PhD, Founder, Chief Executive Officer, and Chair of the Board. “As we move into the second half of this year, our efforts will focus on regulatory progress in Galactosemia and SORD Deficiency, and on Phase 3 clinical readouts in SORD Deficiency and DbCM. We remain steadfast in our commitment to bring govorestat and caficrestat to patients with these devastating diseases in need of treatment.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLT:
- Applied Therapeutics Reports Second Quarter 2023 Financial Results
- Biotech Alert: Searches spiking for these stocks today
- Applied Therapeutics granted pre-NDA meeting by FDA for govorestat
- Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association